FDA posted a CDER warning letter for Harbin Jixianglong Biotech Co., Ltd. on May 19, 2026. The letter covers CGMP concerns tied to quality-unit oversight, supplier qualification, repackaging, relabeling, traceability, process validation, cleaning validation, and records that support API retest dates.
The GLP-1 detail makes the letter useful beyond one firm.
FDA says Harbin Jixianglong purchased semaglutide API from outside suppliers, repackaged and relabeled two batches, changed batch information, and identified Harbin Jixianglong as the manufacturer on the container label. FDA also says one outside facility was not on the Green List for Import Alert 66-80.
FDA did not frame the issue as a routine paperwork gap. The agency said it was concerned the relabeling may have circumvented import-alert safeguards.
Why the record matters
GLP-1 demand has pulled more firms, suppliers, repackagers, relabelers, compounders, distributors, and import channels into the same market. That creates a simple control problem for compliance teams: the label on the container cannot be the only proof of who made the API.
Supplier-quality and regulatory teams should be able to answer four questions before a material reaches a customer, compounder, or finished-product process:
- Who manufactured the API?
- Who repackaged or relabeled it?
- Which batch records support the retest date?
- Does the import pathway match the underlying supplier and facility status?
What FDA expected to see
The warning letter points back to records and controls, not market commentary. Teams tracking GLP-1 supply chains should check whether their files can support:
- Supplier qualification for each actual manufacturer and brokered source.
- Relabeling and repackaging records that preserve the original batch history.
- Quality-unit review before new labels, certificates, or retest dates move forward.
- Cleaning and process-validation support for API handling steps.
- Import-alert and Green List status before relying on a foreign API source.
The point is not to assume every supplier problem involves intent. The point is to make supplier identity provable before FDA, a customer, or a recall investigation asks for the record.
The operating takeaway
GLP-1 enforcement stories often get treated as market headlines. This letter is more specific. FDA focused on whether the firm's records proved the identity, status, and handling history of semaglutide API moving toward the U.S. market.
That is the kind of source-linked signal FDA Warning Monitor tracks: the public FDA record, the operational control behind it, and the compliance teams who need to know before the issue becomes a scramble.
Source
FDA warning letter, Harbin Jixianglong Biotech Co., Ltd., posted May 19, 2026